Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
IPO Year: 2021
Exchange: NASDAQ
Website: codexdna.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2022 | Outperform | Cowen | |
| 10/15/2021 | Outperform | Cowen | |
| 7/13/2021 | $23.00 | Buy | Jefferies |
| 7/13/2021 | Outperform | Cowen & Co. | |
| 7/13/2021 | $30.00 | Overweight | Keybanc |
Cowen resumed coverage of Codex DNA with a rating of Outperform
Cowen resumed coverage of Codex DNA with a rating of Outperform
Jefferies initiated coverage of Codex DNA with a rating of Buy and set a new price target of $23.00
Cowen & Co. initiated coverage of Codex DNA with a rating of Outperform
Keybanc initiated coverage of Codex DNA with a rating of Overweight and set a new price target of $30.00
4 - Telesis Bio Inc. (0001850079) (Issuer)
3 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
3 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
3 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
4 - Telesis Bio Inc. (0001850079) (Issuer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
10-Q - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
10-Q - Telesis Bio Inc. (0001850079) (Filer)
8-K - Telesis Bio Inc. (0001850079) (Filer)
EFFECT - Telesis Bio Inc. (0001850079) (Filer)
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer leveraging Telesis Bio's SOLA platform for enzymatic DNA synthesis technology SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today pre-announced certain preliminary, unaudited financial results for the fourth quarter ended December 31, 2022. The results are subject to the completion of the Company's year-end financial reporting processes, reviews, and audit. Telesis Bio also announced that it has a
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced initiation of work under a collaboration to optimize the development and validation of Telesis Bio's BioXp® Digital-to-Biological Converter™ (DBC) instrument for fully automated manufacturing of on-demand CRISPR-Cas9 guide RNA (gRNA) for genome editing. Over the past several years, CRISPR-Cas9 gRNA technology has emerged as a promising platform for genome editing and cellular engineering by allowing researchers to readily alter genetic sequences. However, rapid production of high-
SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to change its Company name to Telesis Bio. "Our innovative and pioneering spirit, and the versatility and power of our technologies, have enabled us to expand our portfolio to include an array of tools for both synthetic biology and genomics applications. To reflect the expansion, we are announcing a name change to Telesis Bio," said Todd Nelson PhD, CEO of Codex DNA. "Codex DNA was founded on innovation and a mission to inspire and empower researchers to accelerate discovery of scientific breakthroughs. We have introduced ma
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release of BioXp® Error-corrected Libraries kits that enable researchers to automate synthesis of DNA variant libraries on the award-winning BioXp® automated synthetic biology workstation. "This addition to the BioXp® solutions demonstrates a new and expanded application of Codex DNA's proprietary 2-step error correction technology. We believe the ability to automate synthesis of DNA variant libraries on the BioXp® system of up to 64 million variants per well with 2-fold greater fidelity than previously will enable scientists in
SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, will showcase its recently released BioXp™ 9600 system at the World of Technology & Science conference which begins tomorrow in Utrecht, Netherlands. The BioXp™ 9600 system will be showcased at the Codex DNA booth in Hall 7 number A091. The BioXp™ 9600 system, a next-generation high throughput platform that builds biology overnight and at the push of a button empowering scientists to accelerate discovery of new vaccines and biologics, is the third release on the powerful and versatile BioXp™ platform. The fully automated BioXp™ system enables scienti
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release and first shipment of the BioXp™ 9600 system, a next-generation high throughput platform designed to revolutionize synthetic biology workflows. The latest instrument further accelerates the design-build-test process of research and discovery by building biology overnight and at the push of a button. The fully automated BioXp™ system enables scientists to overcome process limitations created by the turnaround time, cost, or complexity of alternative means of building or acquiring DNA and mRNA. The BioXp™ system provides o
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsContinued execution across all areas of the growth strategy: Increased total revenue by 98% over prior year periodGrew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisitionDelivered solid growth in BioXp 3250 instrument placementsExperienced record high BioXp kit revenues, driven by growth in gene fragments, cloning, and DNA library kitsLaunched MyBioXperience, a new e-commerce solution, which dramatically sim
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, August 9, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Codex DNA's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://regi
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsContinued execution across all areas of the growth strategy: Increased total revenue by 98% over prior year periodGrew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisitionDelivered solid growth in BioXp 3250 instrument placementsExperienced record high BioXp kit revenues, driven by growth in gene fragments, cloning, and DNA library kitsLaunched MyBioXperience, a new e-commerce solution, which dramatically sim
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, August 9, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Codex DNA's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://regi
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the first quarter ended March 31, 2022. "In the first quarter of 2022, we delivered robust revenue growth across our product portfolio," said Todd R. Nelson, PhD, CEO of Codex DNA. "With a strong global team, an expanding commercial presence, and groundbreaking enzymatic DNA synthesis technologies in development, we are in an excellent position to deliver on our mission to allow more customers to design and build synthetic DNA to address some of humanity's biggest challenges." Recent HighlightsContinued to execute in al
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its first quarter 2022 financial results on Tuesday, May 10, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, May 10, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company's website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409) 937-888
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided financial guidance for 2022. "Codex DNA's first year as a publicly traded company was successful and productive, as we achieved significant financial and operational objectives," said Todd R. Nelson, PhD, CEO of Codex DNA. "We also took a number of critical steps in the fourth quarter to lay the foundation for the next phase of our growth, which included signing a substantial early access collaboration and licensing agreement with Pfizer, closing a highly
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its fourth quarter 2021 financial results on Tuesday, March 22, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, March 22, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company's website at www.codexdna.com. The conference call can be accessed by dialing (888) 705-0127 (domestic) or (409)
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, announced today that it has agreed to acquire Eton Bioscience, a privately held provider of synthetic biology products and services. "Together with the Eton team, we will be able to accelerate our BioXp system growth strategy within the synthetic biology market," said Todd R. Nelson, PhD, CEO of Codex DNA. "This acquisition will allow our combined company to increase its commercial reach, deliver more robust services with broader customer applications, improve the quality and cost of certain raw materials, and support our highly strategic enzymatic DNA syn
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the third quarter ended September 30, 2021. "Our passion for innovation and vision to accelerate the creation of novel, synthetic biology-enabled solutions are what drives us every day," said Todd R. Nelson, PhD, CEO of Codex DNA. "This passion is reflected in the outstanding progress we've made in our innovative enzymatic DNA synthesis program and other R&D initiatives. In addition, we had a record quarter of BioXp™ system unit and kit sales, and we announced a highly strategic acquisition of Eton Bioscience, which b
SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13D - Telesis Bio Inc. (0001850079) (Subject)
SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)
SC 13G - Codex DNA, Inc. (0001850079) (Filed by)
SC 13G - Codex DNA, Inc. (0001850079) (Filed by)